Carmat Overview
- Status
-
Public
- Employees
-
182
- Stock Symbol
-
ALCAR
- Share Price
-
$0.99
- (As of Thursday Closing)
Carmat General Information
Description
Carmat is a France-based company engaged in the development and production of heart prosthesis. It engages in the development of implantable orthotopic and biocompatible artificial heart organs for the treatment of heart failure patients. The company also develops the product's power supply system and its control and remote diagnosis systems.
Contact Information
Website
www.carmatsa.comCorporate Office
- 36, avenue de l'Europe Building
- Etendard
- 78140 Velizy Villacoublay
- France
Corporate Office
- 36, avenue de l'Europe Building
- Etendard
- 78140 Velizy Villacoublay
- France
Carmat Timeline
Carmat Stock Performance
As of 24-Apr-2025, Carmat’s stock price is $0.99. Its current market cap is $57.3M with 58M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.99 | $0.99 | $0.72 - $4.55 | $57.3M | 58M | 248K | -$1.81 |
Carmat Financials Summary
As of 30-Jun-2024, Carmat has a trailing 12-month revenue of $6.04M.
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 141,540 | 219,574 | 259,101 | 333,461 |
| Revenue | 6,039 | 3,082 | 391 | 2,764 |
| EBITDA | (46,298) | (50,450) | (54,591) | (61,459) |
| Net Income | (57,721) | (58,290) | (56,440) | (73,152) |
| Total Assets | 58,065 | 58,662 | 91,408 | 78,214 |
| Total Debt | 62,706 | 63,725 | 59,366 | 58,897 |
Carmat Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Carmat Comparisons
Industry
Financing
Details
Carmat Competitors (15)
One of Carmat’s 15 competitors is enVVeno Medical, a Formerly PE-Backed company based in Irvine, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| enVVeno Medical | Formerly PE-Backed | Irvine, CA | ||||
| JenaValve Technology | Pending Transaction (M&A) | Irvine, CA | ||||
| Valcare | Venture Capital-Backed | Herzliya, Israel | ||||
| Abiomed | Corporate Backed or Acquired | Danvers, MA | ||||
| ResMed | Corporation | San Diego, CA |
Carmat Patents
Carmat Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| FR-3144913-A1 | System for fixing a heart valve to a cardiac prosthesis and cardiac prosthesis provided with such a fixing system. | Active | 17-Jan-2023 | ||
| EP-4403137-A1 | System for attaching a heart valve to a cardiac prosthesis and cardiac prosthesis provided with such an attachment system. | Pending | 17-Jan-2023 | ||
| FR-3144913-B1 | System for fixing a heart valve on a heart prosthesis and heart prosthesis provided with such a fixing system. | Active | 17-Jan-2023 | ||
| EP-4070848-A1 | Device for connecting an implantable cardiac prosthesis in the vascular system of a patient and cardiac prosthesis equipped with such a connection device | Active | 06-Apr-2021 | ||
| FR-3121348-A1 | Device for connecting an implantable cardiac prosthesis to the vascular network of a patient and cardiac prosthesis provided with such a connection device. | Active | 06-Apr-2021 | A61M60/196 |
Carmat Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Carmat Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Carmat ESG
Risk Overview
Risk Rating
Updated September, 14, 2024
26.92 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 16,048
Rank
Percentile
Healthcare
Industry
of 635
Rank
Percentile
Medical Devices
Subindustry
of 225
Rank
Percentile
Carmat FAQs
-
Where is Carmat headquartered?
Carmat is headquartered in Velizy Villacoublay, France.
-
What is the size of Carmat?
Carmat has 182 total employees.
-
What industry is Carmat in?
Carmat’s primary industry is Therapeutic Devices.
-
Is Carmat a private or public company?
Carmat is a Public company.
-
What is Carmat’s stock symbol?
The ticker symbol for Carmat is ALCAR.
-
What is the current stock price of Carmat?
As of 24-Apr-2025 the stock price of Carmat is $0.99.
-
What is the current market cap of Carmat?
The current market capitalization of Carmat is $57.3M.
-
What is Carmat’s current revenue?
The trailing twelve month revenue for Carmat is $6.04M.
-
Who are Carmat’s competitors?
enVVeno Medical, JenaValve Technology, Valcare, Abiomed, and ResMed are some of the 15 competitors of Carmat.
-
What is Carmat’s annual earnings per share (EPS)?
Carmat’s EPS for 12 months was -$1.81.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
